Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer (NYSE:PFE) has named James List, a former Johnson & Johnson (NYSE:JNJ) executive, as the company’s new chief internal ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 billion. On the other hand, the company’s full-year revenue guidance of $62.5 ...

and internal medicine. The profitability at Pfizer also grew significantly. Q4 2024 adjusted EPS was $0.63, up from $0.10 in Q4 2023, due to higher-margin drug revenues, cost savings, and synergy ...

Vinay Prasad, a hematologist-oncologist known for his vocal opposition to elements of the Covid response, also jumped on Cavazzoni’s move back to Pfizer in a same-day blog post titled “FDA approves ...

Pfizer's BENEGENE-2 study met its primary endpoint ... for haemophilia B was recommended for approval by the EMA’s human medicine committee in December 2022, setting up a decision by the ...

According to the company, these will build its capabilities in genomic medicine, with some Pfizer staff expected to follow the projects to their new home. AZ isn't known for its work in this area ...

Pfizer colleagues at the site followed our established ... “After an initial assessment, there does not appear to be any major damage to the medicine production areas.” ...

NEW YORK — In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and ...